John Crowley, the longtime leader of rare disease drug developer Amicus Therapeutics and a board member of the Biotechnology Innovation Organization, will become the trade organization’s new president ...
CHICAGO, Dec. 18, 2025 /PRNewswire/ -- Amphix Bio today announced the initial closing of a $12.5 million seed financing round to advance its lead therapeutic candidates toward human clinical trials ...
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird bio” or “bluebird”) today announced the U.S. Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results